We are live on ! Find out more
AWGLSCP

ABG-WTT Global Life Science Capital Partners Portfolio holdings

AUM $12.3M
1-Year Est. Return 3.13%
This Fund
S&P 500
This Quarter Est. Return
-10.84%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
–
AUM
$20.8M
AUM Growth
+$15.3M
Cap. Flow
+$16.4M
Cap. Flow %
78.47%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$16.4M

Top Sells

Rank Stock Value
1
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$21

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$17.3M 82.98%
+778,922
New +$16.4M
MDVL
2
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$1.8M 8.65%
300,588
-2
-0% -$21
RPID icon
3
Rapid Micro Biosystems
RPID
$87.2M
$1.12M 5.38%
1,038,296
– –
LUNG icon
4
Pulmonx
LUNG
$94.1M
$622K 2.98%
60,204
– –

Similar funds

M
MetLife New York $12.3M AUM 29% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return
VH
Vitol Holding Rotterdam, Netherlands $11.9M AUM 27.28% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
CCM
Crabel Capital Management Los Angeles, California $10.8M AUM 3.34% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's Q3 2023 Portfolio in Review

As of Q3 2023, ABG-WTT Global Life Science Capital Partners held 4 positions worth $20.8M, up 278% from $5.51M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG-WTT Global Life Science Capital Partners deployed $16.4M of net new capital in Q3 2023, opening 1 new position. Its largest new stake was RayzeBio, Inc. Common Stock: 778,922 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was MedAvail Holdings, Inc. Common Stock, an estimated $21 trimmed.

  • ABG-WTT Global Life Science Capital Partners's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 778,922 shares worth $17.3M.
  • ABG-WTT Global Life Science Capital Partners's biggest Q3 2023 reduction was MedAvail Holdings, Inc. Common Stock, cutting an estimated $21.
  • ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $20.8M portfolio in Q3 2023.
  • ABG-WTT Global Life Science Capital Partners opened 1 new position and closed 0 in Q3 2023.
  • ABG-WTT Global Life Science Capital Partners's portfolio value rose 278% quarter-over-quarter to $20.8M.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.